Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostate Adenocarcinoma 1Papillomavirus Infections 1Osteosarcoma 1Neuroblastoma 1Melanoma 1Head and Neck Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 35Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 23Papillomavirus Vaccines 14Data Collection 7Blood Specimen Collection 7Vaccines 6Vaccines, Synthetic 5Educational Status 5Radiotherapy, Intensity-Modulated 4Human Papillomavirus Recombinant Vaccine nonavalent 4Early Intervention, Educational 4Vaginal Smears 3Surveys and Questionnaires 3Polymerase Chain Reaction 3Paclitaxel 3Methods 3Engerix-B 3Colposcopy 3Cisplatin 3halofantrine 2fludarabine phosphate 2fludarabine 2aldesleukin 2Watchful Waiting 2Taxes 2Patient Navigation 2Papanicolaou Test 2Observation 2Light Coagulation 2Imiquimod 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Papillomavirus Infections × Adjuvants, Pharmaceutic × Clear all
NCT00693615 2016-09-16

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

GlaxoSmithKline

Phase 2 Completed
60 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡